Recombinant 9-valent human papillomavirus vaccine(type 6/11/16/18/31/33/45/52/58) (Jiangsu Recbio Technology/Beijing An Baisheng)

重组人乳头瘤病毒6/11/16/18/31/33/45/52/58型九价疫苗（江苏瑞科生物技术/北京安百胜）

Report date: 2025/12/11 09:50:56

Base Information

Drug NameRecombinant 9-valent human papillomavirus vaccine(type 6/11/16/18/31/33/45/52/58) (Jiangsu Recbio Technology/Beijing An Baisheng)
Drug Alias Name重组人乳头瘤病毒九价疫苗（汉逊酵母）（BFA58佐剂）重组九价HPV疫苗（BFA58佐剂）REC-603
ClassificationVaccines > Application > Prophylactic vaccineVaccines > Vaccine type > Multivalent vaccineVaccines > Biological material > Viral vaccine +[4] 
Mechanisms of ActionImmunostimulants
TargetsNot applicable
Therapy Area/IndicationsPapillomavirus Infections
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaPhase 3 Clinical
Originator CompaniesAbzymo Biosciences Co LtdJiangsu Rec-Biotechnology Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesSaudi Pharmaceutical Industries & Medical Appliances CorpBiological E LtdAbzymo Biosciences Co Ltd +[4] 
Inactive CompaniesN/A
Active IndicationsPapillomavirus Infections
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A